Viral immune T-cells for viral infections after stem cell transplant
Part of Infections clinical trials.
This Phase 2 study tests donor-made immune T-cells that specifically target viruses to treat or prevent viral infections after a stem cell transplant. It may help your body control dangerous viruses like adenovirus, CMV, EBV, and BK virus, while checking safety with different timing of the treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 21 days after your stem cell infusion
- Your doctors must be able to lower steroid medicine to under 0.5 mg/kg prednisone equivalent
- You must not have a life-threatening illness that makes the T-cell infusion risky
- You must not have active acute graft-versus-host disease (GVHD) grade 2 to 4
- You must not have uncontrolled cancer relapse
- You must not have received ATG or alemtuzumab within 2 weeks before the immune T-cell infusion
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies donor-made immune cells (T-cells) given after a stem cell transplant to help your body fight infections. It aims to test how safe the treatment is and whether it supports the immune system in the months after transplant.
This Phase 1 study tests an “off-the-shelf” type of immune cell therapy made to attack several viruses (EBV, CMV, adenovirus, and BK, and possibly JC) in people who had an allogeneic stem cell transplant and still have ongoing viral infection. It may help your body control the virus when standard treatments have not worked or you cannot tolerate them.
This Phase 2 study gives you special “virus-targeting” immune cells (T-cells) to help your body control a current viral infection or virus that has come back (reactivated). It may help reduce the virus activity while you are immunocompromised, meaning your immune system is weaker than usual.
This early-phase study tests donor immune cells made to recognize CMV (a virus) or adenovirus, given to help control virus reactivation after a solid organ or bone marrow transplant. It may help reduce ongoing or worsening viral infection when standard antiviral medicines are hard to tolerate or not working well.
This early-phase (Phase 1) study tests an immune cell treatment (R-MVST) to help people whose immune system has been weakened by a past transplant and who keep getting viral infections reactivated or not responding well to standard treatment. It may help your body control viruses like EBV, CMV, adenovirus, or BK virus.
This trial tests a treatment using specially trained immune cells (virus-specific T-cells) to fight stubborn infections with adenovirus, CMV, or EBV in people with weakened immune systems, such as after a stem cell or organ transplant.
Hear when a new Viral Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.